TY - JOUR
T1 - The Toxicology Investigators Consortium Case Registry—the 2017 Annual Report
AU - On behalf of the Toxicology Investigators Consortium (ToxIC) Study Group
AU - Farrugia, Lynn A.
AU - Rhyee, Sean H.
AU - Campleman, Sharan L.
AU - Judge, Bryan
AU - Kao, Louise
AU - Pizon, Anthony
AU - Porter, Lauren
AU - Riederer, Anne M.
AU - Wiegand, Timothy
AU - Calello, Diane
AU - Wax, Paul M.
AU - Brent, Jeffrey
N1 - Funding Information:
In 2017, ToxIC continued to be supported by a grant on cardiovascular toxicity from the National Institutes of Health, the continuation of our contract with the US Food and Drug Administration, and further unrestricted grant support from BTG International. The latter was used to support the North American Snake Bite Registry.
Funding Information:
Funding Sources This study received funding from the NIH National Institute on Drug Abuse, 1R56DA38366 and 1R01DA037317-01, a data sharing contract with the US Food and Drug Administration and BTG International Inc. (North America).
Publisher Copyright:
© 2018, American College of Medical Toxicology.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - The Toxicology Investigators Consortium (ToxIC) Case Registry was established by the American College of Medical Toxicology in 2010. The Registry collects data from participating sites with the agreement that all bedside medical toxicology consultations will be entered. The objective of this eighth annual report is to summarize the Registry’s 2017 data and activity with its additional 7577 cases. Cases were identified for inclusion in this report by a query of the ToxIC database for any case entered from 1 January to 31 December 2017. Detailed data was collected from these cases and aggregated to provide information which includes demographics (e.g., age, gender, race, ethnicity), reason for medical toxicology evaluation (e.g., intentional pharmaceutical exposure, envenomation, withdrawal from a substance), agent and agent class, clinical signs and symptoms (e.g., vital sign abnormalities, organ system dysfunction), treatments and antidotes administered, fatality, and life support withdrawal data. Females were involved in 50.4% of cases. Transgender demographic information collection was initiated in 2017 to better represent the population and there were 36 cases involving transgender patients. Adults aged 19–65 were the most commonly reported age group. Non-opioid analgesics were the most commonly reported agent class, with acetaminophen again the most common agent reported. There were 93 fatalities reported in 2017. Treatment interventions were frequently reported with 30.6% receiving specific antidotal therapy. Major trends in demographics and exposure characteristics remained similar to past years’ reports. While treatment interventions were commonly required, fatalities were rare.
AB - The Toxicology Investigators Consortium (ToxIC) Case Registry was established by the American College of Medical Toxicology in 2010. The Registry collects data from participating sites with the agreement that all bedside medical toxicology consultations will be entered. The objective of this eighth annual report is to summarize the Registry’s 2017 data and activity with its additional 7577 cases. Cases were identified for inclusion in this report by a query of the ToxIC database for any case entered from 1 January to 31 December 2017. Detailed data was collected from these cases and aggregated to provide information which includes demographics (e.g., age, gender, race, ethnicity), reason for medical toxicology evaluation (e.g., intentional pharmaceutical exposure, envenomation, withdrawal from a substance), agent and agent class, clinical signs and symptoms (e.g., vital sign abnormalities, organ system dysfunction), treatments and antidotes administered, fatality, and life support withdrawal data. Females were involved in 50.4% of cases. Transgender demographic information collection was initiated in 2017 to better represent the population and there were 36 cases involving transgender patients. Adults aged 19–65 were the most commonly reported age group. Non-opioid analgesics were the most commonly reported agent class, with acetaminophen again the most common agent reported. There were 93 fatalities reported in 2017. Treatment interventions were frequently reported with 30.6% receiving specific antidotal therapy. Major trends in demographics and exposure characteristics remained similar to past years’ reports. While treatment interventions were commonly required, fatalities were rare.
KW - Epidemiology
KW - Medical toxicology
KW - Overdose
KW - Poisonings
KW - Surveillance
UR - http://www.scopus.com/inward/record.url?scp=85051654838&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051654838&partnerID=8YFLogxK
U2 - 10.1007/s13181-018-0679-z
DO - 10.1007/s13181-018-0679-z
M3 - Article
C2 - 30094774
AN - SCOPUS:85051654838
SN - 1556-9039
VL - 14
SP - 182
EP - 211
JO - Journal of Medical Toxicology
JF - Journal of Medical Toxicology
IS - 3
ER -